CClinicalTrials.gg
Not yet recruitingNCT05928858Updated Aug 1, 2023

Clinical And Radiographic Evaluation Of Premixed Bio-ceramic MTA In Indirect Pulp Capping Of Young Permanent Molars

A Phase 3 interventional study of Premixed Bio-ceramic MTA and Calcium hydroxide in Indirect Pulp Capping, sponsored by Cairo University. Not yet recruiting. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Cairo University · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The present study aims to evaluate the clinical and radiographic success of premixed bio-ceramic MTA versus calcium hydroxide in indirect pulp capping of young permanent molars.

Read the detailed description

Researchers are still in search of an ideal material for pulp capping, and they evaluated numerous dental materials. For many decades, calcium hydroxide has been the 'gold standard' material for maintaining pulp vitality. Both clinically and histologically, it has been found to produce satisfactory results in indirect and direct pulp capping because it can stimulate the formation of tertiary dentine by the pulp and it has antimicrobial properties.

Due to the drawbacks of calcium hydroxide, several materials have been developed, such as NeoPUTTY which is premixed bio-ceramic Mineral Trioxide Aggregate (MTA) that triggers hydroxyapatite. Its firm, non-tacky consistency, wash-out resistance, and bioactivity make it a pediatric dentists' preferred material for every pulp need. It also delivers ready-to-use material for immediate placement with zero waste, saving cost and chair time.

02

Conditions studied

  • Indirect Pulp Capping

Keywords

  • neoputty
  • premixed bioceramic MTA
  • young permanent teeth
  • calcium hydroxide
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients who have young permanent molars with deep carious lesions.
  • Restorable young permanent molars with no clinical symptoms of irreversible pulpitis.
  • Permanent molars with no clinical or radiographic signs of pulp necrosis including swelling, fistula, pain on percussion,pathologic tooth mobility, thickening of the periodontal ligament space, radiolucency at the periapical area.

Exclusion criteria

Exclusion Criteria:

  • Medically compromised patients who have systemic disease.
  • Uncooperative patients who refuse treatment
  • Permanent molars that were previously restored
  • Children whose parents or caregivers refuse to participate in the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Premixed Bio-ceramic MTA

    Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration

    Drug: Premixed Bio-ceramic MTA

  • Active comparator
    Calcium hydroxide

    Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration

    Drug: Calcium hydroxide

Interventions

  • DrugPremixed Bio-ceramic MTA

    Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration

    Also known as: Neoputty

  • DrugCalcium hydroxide

    Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration

    Also known as: Dycal, Hydcal

06

What researchers measure

Primary outcomes

  1. Immediate Postoperative pain

    post operative pain by Verbal analogue scale.It is a 10 cm long horizontal line with points labeled from 0 to 10 where (0) indicates no pain, (1-3) mild pain, (4-6) moderate pain, and (7-10) severe pain.

    Time frame: one week

Secondary outcomes

  1. The thickness of newly formed dentin

    The thickness of newly formed dentin will be assessed in Mm through Digora software

    Time frame: 3,6,9,12 month

  2. Soft tissue pathology

    Swelling, sinus tract, fistula, mobility and pain on percussion will be assessed by clinical examination either present or not (binary)

    Time frame: 3,6,9,12 month

  3. Radiographic changes

    Radiolucency at the periapical or furcation area and Internal or external root resorption will be assessed through a digital periapical intraoral radiograph either present or not ( Binary)

    Time frame: 3,6,9,12 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — IPD can be shared with citation to the investigator but not personal data of the patients to protect confidentiality.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05928858
Lead sponsor
Cairo University
Responsible party
Aya Adel Abd El-Hafez Osman Hamza (Assistant lecturer, Cairo University) — Principal investigator
First posted
Jul 3, 2023
Start date
Sep 2023 (estimated)
Primary completion
Jun 2024 (estimated)
Completion
Sep 2024 (estimated)
Last update
Aug 1, 2023

Study contacts

Aya Ad Hamza, Phd
Contact
aya.adel@dentistry.cu.edu.eg
01062315566
Sara Ah Mahmoud, Professor
Contact
Aya Ad Hamza, Phd
principal investigator · Cairo University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion